Richard Thomas Williams - 01 Mar 2023 Form 4 Insider Report for Kinnate Biopharma Inc.

Role
Chief Medical Officer
Signature
/s/ Mark A. Meltz, as attorney-in-fact
Issuer symbol
N/A
Transactions as of
01 Mar 2023
Net transactions value
-$3,324
Form type
4
Filing time
03 Mar 2023, 16:58:44 UTC
Previous filing
14 Feb 2023
Next filing
05 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNTE Common Stock Tax liability $3,324 -638 -0.94% $5.21 67,295 01 Mar 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were forfeited to cover a tax obligation resulting form the quarterly vesting of RSU's granted to the Reporting Person by the Issuer.
F2 Includes 21,875 shares represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of the Issuer. A portion of the RSUs vest each quarter, subject to the Reporting Person's continued service as of each vesting date.